Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial.

Colhoun HM, Lingvay I, Brown PM, Deanfield J, Brown-Frandsen K, Kahn SE, Plutzky J, Node K, Parkhomenko A, Rydén L, Wilding JPH, Mann JFE and 4 more

Show all authors

Tuttle KR, Idorn T, Rathor N, Lincoff AM

Nature medicine25 May 2024Cited by 188 (Europe PMC)

PMID38796653PMCIDPMC11271413DOI10.1038/s41591-024-03015-5PepBankPUB-38796653

Download PDF PubMedAsk about this study

Jump to 3 results

Summary

The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes. In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial. The incidence of the pre-specified main composite kidney endpoint (death from kidney disease, initiation of chronic kidney replacement therapy, onset of persistent estimated glomerular filtration rate (eGFR) -1 1.73 m^-², persistent ≥50% reduction in eGFR or onset of persistent macroalbuminuria) was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02. The treatment benefit at 104 weeks for eGFR was 0.75 ml min^-1 1.73 m^-² (95% CI 0.43, 1.06; P < 0.001) overall and 2.19 ml min^-1 1.73 m^-² (95% CI 1.00, 3.38; P -1 1.73 m^-². These results suggest a benefit of semaglutide on kidney outcomes in individuals with overweight/obesity, without diabetes.ClinicalTrials.gov identifier: NCT03574597 .

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and cardiovascular disease without diabetes, the main composite kidney endpoint occurred less often with semaglutide than with placebo.
In plain wordsIn adults with overweight or obesity and heart disease, semaglutide led to fewer serious kidney events than placebo.
Peptide
Semaglutide
Outcome
DecreaseMain composite kidney endpoint
Study
n = 17,604
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
2.4 mg once weeklyAs given in this study (human).
Measurements
Hazard ratio
0.78 ratio
composite kidney endpoint
Incidence
1.8%
semaglutide
Incidence
2.2%
placebo
Source sentences
Summary
was lower with semaglutide (1.8%) versus placebo (2.2%): hazard ratio (HR) = 0.78; 95% confidence interval (CI) 0.63, 0.96; P = 0.02.
2 context sentences(design, population, supporting numbers)
Summary · context
The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes.
Summary · context
In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial.
Show in the study text Report a problemFND-3879665301
02HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and cardiovascular disease without diabetes, semaglutide gave a higher eGFR than placebo at 104 weeks overall.
In plain wordsIn adults with overweight or obesity and heart disease, semaglutide kept kidney filtration higher than placebo after 104 weeks.
Peptide
Semaglutide
Outcome
IncreaseeGFR treatment benefit at 104 weeks, overall
Study
n = 17,604
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
2.4 mg once weeklyAs given in this study (human).
Measurements
eGFR treatment benefit
0.75 ml min-1 1.73 m-2
overall
Source sentences
Summary
The treatment benefit at 104 weeks for eGFR was 0.75 ml min^-1 1.73 m^-² (95% CI 0.43, 1.06; P < 0.001) overall
2 context sentences(design, population, supporting numbers)
Summary · context
The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes.
Summary · context
In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial.
Show in the study text Report a problemFND-3879665302
03HumanRandomized controlled trialEfficacy outcome
In adults with overweight or obesity and cardiovascular disease without diabetes and with low baseline eGFR, semaglutide gave a larger eGFR benefit than placebo at 104 weeks.
In plain wordsIn adults with heart disease and reduced kidney function, semaglutide kept kidney filtration higher than placebo after 104 weeks.
Peptide
Semaglutide
Outcome
IncreaseeGFR treatment benefit at 104 weeks, baseline eGFR below 60
Study
n: not reported in source
Comparator
Placebo
Outcome group
Kidney function · Kidney and urinary
Studied dose
2.4 mg once weeklyAs given in this study (human).
Measurements
eGFR treatment benefit
2.19 ml min-1 1.73 m-2
baseline eGFR <60
Source sentences
Summary
and 2.19 ml min^-1 1.73 m^-² (95% CI 1.00, 3.38; P -1 1.73 m^-².
2 context sentences(design, population, supporting numbers)
Summary · context
The SELECT trial previously reported a 20% reduction in major adverse cardiovascular events with semaglutide (n = 8,803) versus placebo (n = 8,801) in patients with overweight/obesity and established cardiovascular disease, without diabetes.
Summary · context
In the present study, we examined the effect of once-weekly semaglutide 2.4 mg on kidney outcomes in the SELECT trial.
Show in the study text Report a problemFND-3879665303

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT03574597

Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity

Novo Nordisk A/Sn = 17,60424 Oct 2018 to 29 Jun 2023

Overweight · Obesity

Trial page ClinicalTrials.govUpdated 30 Aug 2024

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.